A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
Key facts
- Study ID
- NCT05935033
- Run by
- AbbVie
- People needed
- 38
- Starts
- 2023-06-30
- Expected to finish
- 2025-02-21
- Last updated by the study team
- 2025-04-04
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Miami, Florida — Miami, Florida, United States
- Orlando, Florida — Orlando, Florida, United States
- San Antonio, Texas — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.